- Home
- PCVX vs GPI Comparison
PCVX vs GPI Comparison
Compare PCVX & GPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | GPI |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.6B |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | PCVX | GPI |
|---|---|---|
| Price | $46.79 | $394.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $105.00 | ★ $475.86 |
| AVG Volume (30 Days) | ★ 1.1M | 145.5K |
| Earning Date | 02-24-2026 | 01-29-2026 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 28.66 |
| Revenue | N/A | ★ $22,537,600,000.00 |
| Revenue This Year | N/A | $14.63 |
| Revenue Next Year | N/A | $3.33 |
| P/E Ratio | ★ N/A | $13.83 |
| Revenue Growth | N/A | ★ 19.45 |
| 52 Week Low | $27.66 | $355.91 |
| 52 Week High | $93.77 | $490.09 |
Technical Indicators
Market Signals| Indicator | PCVX | GPI |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 43.06 |
| Support Level | $44.57 | $389.99 |
| Resistance Level | $49.55 | $407.79 |
| Average True Range (ATR) | 2.13 | 9.67 |
| MACD | 0.15 | -0.27 |
| Stochastic Oscillator | 52.90 | 33.12 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About GPI Group 1 Automotive Inc.
Group 1 owns and operates 39 collision centers and 260 automotive dealerships in the US and the UK, offering 35 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 33.5% of new-vehicle unit volume in 2024 and the UK 22.6%. Texas, Massachusetts, and California combined was 48.5%. Revenue in 2024 totaled $19.9 billion. The August 2024 Inchcape UK deal adds about $2.7 billion of annual revenue and 54 stores. The firm entered the UK in 2007 and has 116 stores and about one-third of its new vehicle unit volume there. Group 1 was founded in 1995 and is based in Houston.